Clinical trial
A Phase 1 Randomized, Observer-Blinded,Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus F Protein Particle Vaccine in Healthy Adults
NCT01290419 is registered in ClinicalTrials.gov with Novavax as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Randomized, Observer-Blinded,Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus F Protein Particle Vaccine in Healthy Adults
- Lead sponsor
- Novavax
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- December 31, 2011
- Enrollment
- 150 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.